Home › Ewing Sarcoma › Pennsylvania
Ewing Sarcoma clinical trials in Pennsylvania
10 studies for Ewing Sarcoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Nov 12, 2026 · NCT06541262Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 2 to 30 · All sexes · Updated Nov 5, 2026 · NCT05734066Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Oct 30, 2026 · NCT06395103Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
- Childrens Hospital of Philadelphia, Philadelphia
- University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh, Pittsburgh
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Oct 29, 2026 · NCT07297979Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 2
Ages 0 to 50 · All sexes · Updated Oct 6, 2026 · NCT07321912Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Children's Hospital of Philadelphia- Center for Childhood Cancer Research, Philadelphia
- University of Pennsylvania Abramson Cancer Center, Philadelphia
RecruitingPhase 1
Ages 12 to 85 · All sexes · Updated Sep 8, 2026 · NCT03715933Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey
RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
- Children's Hospital of Philadelphia, Philadelphia
- University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 5 to 40 · All sexes · Updated Sep 3, 2026 · NCT06156410Lurbinectedin in FET-Fused Tumors
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 10 and older · All sexes · Updated Sep 2, 2026 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.